Pseudoxanthoma Elasticum- Pipeline Insight, 2019
This report can be delivered to the clients within 24 Hours
"Pseudoxanthoma Elasticum- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pseudoxanthoma Elasticum pipeline landscape is provided which includes the disease overview and Pseudoxanthoma Elasticum treatment guidelines. The assessment part of the report embraces, in depth Pseudoxanthoma Elasticum commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pseudoxanthoma Elasticum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pseudoxanthoma Elasticum Understanding
Pseudoxanthoma Elasticum (PXE) also known as Groenblad-Strandberg Syndrome is a progressive disorder that is characterized by the accumulation of deposits of calcium and other minerals (mineralization) in elastic fibers. Elastic fibers are a component of connective tissue, which provides strength and flexibility to structures throughout the body. In PXE, mineralization can affect elastic fibers in the skin, eyes, and blood vessels, and less frequently in other areas such as the digestive tract. People with PXE may have yellowish bumps called papules on their necks, underarms, and other areas of skin that touch when a joint bends (flexor areas). They may also have abnormalities in the eyes, such as a change in the pigmented cells of the retina. Another eye abnormality known as angioid streaks occurs when tiny breaks form in the layer of tissue under the retina called Bruch's membrane. Bleeding and scarring of the retina may also occur, which can cause vision loss.
Pseudoxanthoma Elasticum Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Pseudoxanthoma Elasticum targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Pseudoxanthoma Elasticum pipeline report covers 4+ companies. Some of the key players include Inositec (INS-3001), Inozyme (INZ-701) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Pseudoxanthoma Elasticum Analytical Perspective by DelveInsight
Scope of the report
"Pseudoxanthoma Elasticum- Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pseudoxanthoma Elasticum pipeline landscape is provided which includes the disease overview and Pseudoxanthoma Elasticum treatment guidelines. The assessment part of the report embraces, in depth Pseudoxanthoma Elasticum commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pseudoxanthoma Elasticum collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Pseudoxanthoma Elasticum Understanding
Pseudoxanthoma Elasticum (PXE) also known as Groenblad-Strandberg Syndrome is a progressive disorder that is characterized by the accumulation of deposits of calcium and other minerals (mineralization) in elastic fibers. Elastic fibers are a component of connective tissue, which provides strength and flexibility to structures throughout the body. In PXE, mineralization can affect elastic fibers in the skin, eyes, and blood vessels, and less frequently in other areas such as the digestive tract. People with PXE may have yellowish bumps called papules on their necks, underarms, and other areas of skin that touch when a joint bends (flexor areas). They may also have abnormalities in the eyes, such as a change in the pigmented cells of the retina. Another eye abnormality known as angioid streaks occurs when tiny breaks form in the layer of tissue under the retina called Bruch's membrane. Bleeding and scarring of the retina may also occur, which can cause vision loss.
Pseudoxanthoma Elasticum Pipeline Development Activities
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Pseudoxanthoma Elasticum targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Pseudoxanthoma Elasticum pipeline report covers 4+ companies. Some of the key players include Inositec (INS-3001), Inozyme (INZ-701) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
Pseudoxanthoma Elasticum Analytical Perspective by DelveInsight
- In-depth Pseudoxanthoma Elasticum Commercial Assessment of products
- Pseudoxanthoma Elasticum Clinical Assessment of products
Scope of the report
- The Pseudoxanthoma Elasticum report provides an overview of therapeutic pipeline activity for Pseudoxanthoma Elasticum across the complete product development cycle including all clinical and non-clinical stages
- It comprises of detailed profiles of Pseudoxanthoma Elasticum therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
- Detailed Pseudoxanthoma Elasticum Research and Development progress and trial details, results wherever available, are also included in the pipeline study
- Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Pseudoxanthoma Elasticum
- Establish a comprehensive understanding of the current pipeline scenario across Pseudoxanthoma Elasticum to formulate effective R&D strategies
- Assess challenges and opportunities that influence Pseudoxanthoma Elasticum R&D
- Develop strategic initiatives by understanding the focus areas of leading companies.
- Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
- Get in detail information of each product with updated information on each project along with key milestones
- Devise Pseudoxanthoma Elasticum in licensing and out licensing strategies by identifying prospective partners with progressing projects for Pseudoxanthoma Elasticum to enhance and expand business potential and scope
- Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION
2. PSEUDOXANTHOMA ELASTICUM (GROENBLAD-STRANDBERG SYNDROME)
2.1. Pseudoxanthoma Elasticum Disease Overview
2.2. Pseudoxanthoma Elasticum History
2.3. Pseudoxanthoma Elasticum Symptoms
2.4. Pseudoxanthoma Elasticum Causes
2.5. Pseudoxanthoma Elasticum Pathophysiology
2.6. Pseudoxanthoma Elasticum Diagnosis
2.6.1. Diagnostic Guidelines
3. PSEUDOXANTHOMA ELASTICUM CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. PSEUDOXANTHOMA ELASTICUM - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Pseudoxanthoma Elasticum companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Pseudoxanthoma Elasticum Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Pseudoxanthoma Elasticum Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. PSEUDOXANTHOMA ELASTICUM PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. PSEUDOXANTHOMA ELASTICUM -PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. INS-3001- Inositec
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. INZ-701- Inozyme
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. PSEUDOXANTHOMA ELASTICUM KEY COMPANIES
8.1. Regeneron Pharmaceuticals
8.2. Novartis Ophthalmics
8.3. Inositec
8.4. Inozyme
9. PSEUDOXANTHOMA ELASTICUM KEY PRODUCTS
9.1. Aflibercept
9.2. Ranibizumab
9.3. INS-3001
9.4. INZ-701
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. PSEUDOXANTHOMA ELASTICUM - UNMET NEEDS
12. PSEUDOXANTHOMA ELASTICUM - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
2. PSEUDOXANTHOMA ELASTICUM (GROENBLAD-STRANDBERG SYNDROME)
2.1. Pseudoxanthoma Elasticum Disease Overview
2.2. Pseudoxanthoma Elasticum History
2.3. Pseudoxanthoma Elasticum Symptoms
2.4. Pseudoxanthoma Elasticum Causes
2.5. Pseudoxanthoma Elasticum Pathophysiology
2.6. Pseudoxanthoma Elasticum Diagnosis
2.6.1. Diagnostic Guidelines
3. PSEUDOXANTHOMA ELASTICUM CURRENT TREATMENT PATTERNS
3.1. Treatment Guidelines
4. PSEUDOXANTHOMA ELASTICUM - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE
4.1. In-depth Commercial Assessment
4.1.1. Pseudoxanthoma Elasticum companies collaborations, Licensing, Acquisition –Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Pseudoxanthoma Elasticum Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Pseudoxanthoma Elasticum Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
4.2.1. Assessment by Phase of Development
4.2.2. Assessment by Product Type (Mono / Combination)
4.2.2.1. Assessment by Stage and Product Type
4.2.3. Assessment by Route of Administration
4.2.3.1. Assessment by Stage and Route of Administration
4.2.4. Assessment by Molecule Type
4.2.4.1. Assessment by Stage and Molecule Type
4.2.5. Assessment by MOA
4.2.5.1. Assessment by Stage and MOA
5. PSEUDOXANTHOMA ELASTICUM PIPELINE THERAPEUTICS
5.1. Late Stage Products (Phase-III)
5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
5.4.1. Comparative Analysis
5.5. Inactive Products
6. PSEUDOXANTHOMA ELASTICUM -PRODUCTS ANALYSIS
6.1. Product Profiles
6.1.1. INS-3001- Inositec
6.1.1.1. Product Description
6.1.1.1.1. Product Overview
6.1.1.1.2. Mechanism of Action
6.1.1.2. Research and Development
6.1.1.2.1. Clinical Studies
6.1.1.2.1.1. Detailed Study Description
6.1.1.2.1.2. Study Results
6.1.1.2.1.3. Clinical Trials: Tabular View
6.1.1.3. Product Development Activities
6.1.1.3.1. Tabulated Product Summary
6.1.1.3.1.1. General Description Table
6.1.2. INZ-701- Inozyme
6.1.2.1. Product Description
6.1.2.1.1. Product Overview
6.1.2.1.2. Mechanism of Action
6.1.2.2. Research and Development
6.1.2.2.1. Clinical Studies
6.1.2.2.1.1. Detailed Study Description
6.1.2.2.1.2. Study Results
6.1.2.2.1.3. Clinical Trials: Tabular View
6.1.2.3. Product Development Activities
6.1.2.3.1. Tabulated Product Summary
6.1.2.3.1.1. General Description Table
To be continued in the report…………………………
7. RECENT TECHNOLOGIES
8. PSEUDOXANTHOMA ELASTICUM KEY COMPANIES
8.1. Regeneron Pharmaceuticals
8.2. Novartis Ophthalmics
8.3. Inositec
8.4. Inozyme
9. PSEUDOXANTHOMA ELASTICUM KEY PRODUCTS
9.1. Aflibercept
9.2. Ranibizumab
9.3. INS-3001
9.4. INZ-701
10. DORMANT AND DISCONTINUED PRODUCTS
10.1. Dormant Products
10.1.1. Reasons for being dormant
10.2. Discontinued Products
10.2.1. Reasons for the discontinuation
11. PSEUDOXANTHOMA ELASTICUM - UNMET NEEDS
12. PSEUDOXANTHOMA ELASTICUM - FUTURE PERSPECTIVES
13. APPENDIX
14. REPORT METHODOLOGY
14.1. Secondary Research
14.2. Expert Panel Validation
LIST OF TABLES
Table 1. Pseudoxanthoma Elasticum Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Pseudoxanthoma Elasticum Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
Table 1. Pseudoxanthoma Elasticum Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Pseudoxanthoma Elasticum Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products
LIST OF FIGURES
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Pseudoxanthoma Elasticum companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Pseudoxanthoma Elasticum Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
Regeneron Pharmaceuticals
Novartis Ophthalmics
Alexion
Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Pseudoxanthoma Elasticum companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Pseudoxanthoma Elasticum Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs
KEY COMPANIES
Regeneron Pharmaceuticals
Novartis Ophthalmics
Alexion
